MANE MANE
Company Profile ↓Company Overview
MANE (MANE) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Generates a return on equity of 57.8%, reflecting efficient use of shareholder capital.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +194.94% |
| 6 Months: | - |
| 3 Months: | -3.01% |
| 1 Month: | -4.67% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- RSI (14)51.53 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 57.8%.
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Operating Income | -12.91M | -29.86M |
| Net Income | -12.40M | -27.23M |
| Diluted EPS | -19.79 | -1.32 |
| R&D Expense | 11.45M | 20.93M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Operating Income | -26.78M | -72.35M |
| Net Income | -26.49M | -70.00M |
| Diluted EPS | -37.05 | -111.91 |
| R&D Expense | 23.28M | 62.06M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Total Assets | - | 55.53M | 152.62M |
| Total Equity | -22.24M | -48.48M | -121.01M |
| Cash & Equivalents | - | 53.08M | 21.77M |
| Total Liabilities | - | 4.72M | 9.16M |
| Current Liabilities | - | 4.72M | 9.15M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Operating Cash Flow | -23.69M | -71.60M |
| Investing Cash Flow | 0 | -118.86M |
| Financing Cash Flow | 60.48M | 159.14M |
| Capital Expenditure | -0 | -24.00K |
| Free Cash Flow | -23.69M | -71.63M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Gross Margin % | - | - |
| Operating Margin % | - | - |
| Net Margin % | - | - |
| ROE % | 54.6% | 57.8% |
| ROCE % | -52.7% | -50.4% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for MANE
Top Veradermics (MANE) Competitors 2026 - MarketBeat
<a href="https://news.google.com/rss/articles/CBMifkFVX3lxTE9PX0RJOVQ3c3FPXzZyRzdjU09OVnNZemtKbk8tMDlSMl8zaGpJanA1MEdNUHpwRnFOTm1DMnZEa0pMdnpCdGJ2VDNuOGJZRk9yMGJVSnFBc0hPakJqQTBzX09JY3V6V2pUOFd6V2JsZ1ZZQk5ldkpFMTVnV2JYUQ?oc=5" target="_blan…
Can Veradermics (MANE) Climb 27.65% to Reach the Level Wall Street Analysts Expect? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxNMUZ1WVJCZjNOS0htSUlscEJ6RzFKY283WFpIeDY5TmJia1JJc3RsUGl2WXprSWRHX0hSa051T2NUbXFDTGJDbTdvYnQ1UUMtY2x4WWx3ME13NUd4Sk5yYnJPQ0pKcnhmdVUxTC1xMlZVOGMwRjN4NU8xWmkwdDZteENmYldxalQxRFM5Mz…
Female Pattern Hair-Loss Results Set for Veradermics Webcast - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxNakd0VEw0WW1SalVVWkNWTml6M0k2TVVfdnJ3YWVsbXd5MDMxcFJNSXQtMUNIc2VYak9tMTY0SWNsdl9HU3hCWm9sWjRvYjRmV3lTTEVPZmVTU3A0Y05QY3B4YmVGTDIzWGFvOVRMbnNnRE9YQUxSVk1peEZ4QzdGSmFwcG5DLWpjdHBEUj…
Veradermics, Incorporated Revenue Breakdown – NYSE:MANE - TradingView
<a href="https://news.google.com/rss/articles/CBMidEFVX3lxTE96bkhvNjlpZmZLY3BjZUtCcmwxdjBBMzBWTERHbVJHOGJsc1RJODJKNVVobDQwVVFJWVFpYnVqVjZudjVIbkhfZXh2MDlvemJqQXJNY1V4Wi1hYkV6bERDNjVUSGRFZEN6UjByaV9PR2JnMEll?oc=5" target="_blank">Veradermics…
Veradermics, Incorporated (NYSE: MANE) Share Price, MANE Stock News, MANE Share Price & Updates - Kalkine
<a href="https://news.google.com/rss/articles/CBMiU0FVX3lxTFBSQ3lGa2twMXdPbll2T2NNclJOaEtaYzItLXA4UDVmZV9KN1ZGUjVtVExsN2hyZXhMVVdXc1NPQlNEUVFmSnNMQmZDalgwMFdrOC1V?oc=5" target="_blank">Veradermics, Incorporated (NYSE: MANE) Share Price, MAN…
Should I buy Veradermics Incorporated (MANE) - Zacks Investment Research
<a href="https://news.google.com/rss/articles/CBMibEFVX3lxTE4wbWVqTjdxRVl3RGhvd201WnBIamVvTUgyejhuWXg4TUlfaGtBbHFVOWFSb2xKQ2NlN3pRU1F6WF9NNkdqdjJsYUpfczVEU0RNakpkYnlJOWZZNXBuZWVMcUVFcklDXzdFTVVmaQ?oc=5" target="_blank">Should I buy Veraderm…
MANE — Frequently Asked Questions
What is the current share price of MANE?
As of 2026-08-05 17:25 PDT, MANE trades at $111.34 on NASDAQ/NYSE. Its 52-week range is $37.03 to $129.74.
What is the P/E ratio of MANE?
MANE trades at a trailing price-to-earnings (P/E) ratio of -0.99.
What is the return on equity (ROE) of MANE?
MANE has a return on equity (ROE) of 57.84%. Its return on capital employed (ROCE) is -50.43%.
Is MANE a good stock to buy?
This page provides a data-driven analysis of MANE, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.